·作為首款經(jīng)過驗證的原研注射用聚左旋乳酸填充劑，塑妍萃®的新數(shù)據(jù)強調(diào)了其對所有三層皮膚組織的產(chǎn)生療效，并與其他生物刺激劑進(jìn)行了對比，進(jìn)一步突出其獨特效果。8-12

·高德美將發(fā)布關(guān)于新型液態(tài)A型肉毒毒素（RelabotulinumtoxinA）的新數(shù)據(jù)。這是首款且唯一一款通過 PEARL?技術(shù)研發(fā)的即用型液態(tài)肉毒毒素，目前已在歐洲多個國家和地區(qū)上市。本次數(shù)據(jù)包括 IIIb 期 RELAX 試驗的結(jié)果，進(jìn)一步證明了其長期療效和高患者滿意度，這一成果也在 READY 臨床試驗項目中得到過驗證1-7

·瑞藍(lán)系列產(chǎn)品的最新數(shù)據(jù)突出了其在保持面部表情自然性方面的卓越能力，并揭示了由高德美創(chuàng)新 NASHA HD?技術(shù)驅(qū)動的新型透明質(zhì)酸（HA）注射產(chǎn)品瑞藍(lán) SHAYPE（尚未于中國大陸地區(qū)上市）在常用 HA 填充劑中擁有最高的 G’值13,14

·這些數(shù)據(jù)結(jié)合三場專題研討會、一場關(guān)于藥物引起的體重減輕對皮膚美學(xué)影響的大師班，以及多場“專家見面會”，再次展示并凸顯了高德美廣泛且經(jīng)臨床驗證的產(chǎn)品組合，進(jìn)一步確立了其作為皮膚學(xué)領(lǐng)域的專業(yè)領(lǐng)導(dǎo)地位

近日，高德美將在2025年英卡思國際整形美容暨皮膚抗衰老醫(yī)學(xué)大會（IMCAS）上展示其創(chuàng)新美學(xué)產(chǎn)品組合的最新進(jìn)展。大會將于1月30日至2月1日在法國巴黎舉行。高德美將分享十項研究電子海報，展示其注射型美學(xué)產(chǎn)品的差異化數(shù)據(jù)，包括新型液態(tài)A型肉毒毒素（RelabotulinumtoxinA）、塑妍萃®和瑞藍(lán)系列。此外，高德美還將與合作伙伴共同舉辦三場專題研討會、一場大師班、五場“專家見面會”，并設(shè)立互動展位，重點展示新型液態(tài)A型肉毒毒素的強大優(yōu)勢。

“今年在 IMCAS 大會上的廣泛參與，讓我們有機會不僅展示我們廣泛而創(chuàng)新的注射美學(xué)產(chǎn)品組合的最新進(jìn)展，同時通過信息共享和見解交流，與行業(yè)各界進(jìn)行有意義的互動。我們在 IMCAS 的活動充分體現(xiàn)了我們的綜合皮膚學(xué)戰(zhàn)略，凸顯了產(chǎn)品優(yōu)勢，同時鞏固了高德美作為膚學(xué)領(lǐng)域的領(lǐng)導(dǎo)者地位?！备叩旅廊蜓邪l(fā)負(fù)責(zé)人、醫(yī)學(xué)博士、哲學(xué)博士Baldo Scassellati Sforzolini表示。

行業(yè)廣泛注射美學(xué)產(chǎn)品組合的最新數(shù)據(jù)更新

高德美將發(fā)布關(guān)于塑妍萃®的最新數(shù)據(jù)。塑妍萃®是全球首款原研注射用聚左旋乳酸填充劑，采用獨特的PLLA-SCA?（聚左旋乳酸）配方。8-12最新數(shù)據(jù)顯示，PLLA-SCA?（聚左旋乳酸）具有強大的再生特性，并能對皮膚三層結(jié)構(gòu)起作用，突出其在再生美學(xué)領(lǐng)域的關(guān)鍵地位，包括其與其他產(chǎn)品相比的優(yōu)勢。19-21研究表明，塑妍萃®能刺激皮膚中的關(guān)鍵成分，包括膠原蛋白、彈性蛋白和脂肪組織。同時強調(diào)了其良好的安全性。19-21另一項比較研究發(fā)現(xiàn)，將塑妍萃®與 Alastin® 聯(lián)合用于中面部，能產(chǎn)生協(xié)同效果，對抗衰老皮膚并提升患者體驗。22

最新數(shù)據(jù)還將包含 IIIb 期 RELAX 研究的成果。該研究調(diào)查了新型液態(tài)A型肉毒毒素在單劑量治療后長達(dá)12 個月內(nèi)對中重度眉間紋的長期美學(xué)改善及患者滿意度。這項研究進(jìn)一步支持了先前 READY 臨床試驗項目的數(shù)據(jù)，顯示高達(dá)39%新型液態(tài)A型肉毒毒素治療時，高達(dá) 39% 的患者從第一天起就看到效果，高達(dá) 75% 的患者在治療眉間紋和魚尾紋后可在六個月內(nèi)維持改善。3,4,7

其他研究數(shù)據(jù)將進(jìn)一步凸顯新型液態(tài)A型肉毒毒素的科學(xué)優(yōu)勢，包括高德美專利 PEARLTM 技術(shù)對分子完整性的保護(hù)作用，以及在新型液態(tài)A型肉毒毒素的 III 期試驗重未發(fā)現(xiàn)中和抗體的形成。16,17此外，將發(fā)布來自 READY - 1 - 3 試驗的匯總事后分析，分析涵蓋1700多名具有不同膚色、種族和民族背景的患者，進(jìn)一步驗證了新型液態(tài)A型肉毒毒素的療效。18

此外，一場主題為“超越 Relfydess：引領(lǐng)未來”的專題研討會將于歐洲中部時間1月 31日（星期五）下午 2:00至3:30在 Grand Amphi 舉行，會上將展示新型液態(tài)A型肉毒毒素的臨床表現(xiàn)和創(chuàng)新的容積注射方法，并進(jìn)行現(xiàn)場注射演示。在高德美展位（#L212），專家還將深入探討新型液態(tài)A型肉毒毒素背后的前沿科學(xué)與PEARLTM技術(shù)。

高德美還將公布三項關(guān)于瑞藍(lán)系列產(chǎn)品的新匯總數(shù)據(jù)，顯示使用瑞藍(lán)· Refyne?（尚未于中國大陸地區(qū)上市）和瑞藍(lán)·定采®進(jìn)行治療不僅能提升面部吸引力和年輕感，還能在面部靜態(tài)和動態(tài)表情保持自然感。23此外，作為高德美透明質(zhì)酸（HA）產(chǎn)品組合中的新成員，瑞藍(lán) SHAYPE 的凝膠數(shù)據(jù)也將首次亮相。瑞藍(lán) SHAYPE采用高德美創(chuàng)新的 NASHA HD 技術(shù)，具備更高的交聯(lián)效率和更高的 HA 含量,數(shù)據(jù)顯示其G’值為現(xiàn)有 HA 填充劑中最高，表明其凝膠強度和硬度更優(yōu)，非常適合用于下面部塑形。14

與皮膚病學(xué)界的交流互動

除了分享最新數(shù)據(jù)，IMCAS 世界大會也是與更廣泛的皮膚病學(xué)界建立聯(lián)系的重要機會，旨在促進(jìn)最佳實踐的交流并收集關(guān)鍵見解，為未來的創(chuàng)新提供指導(dǎo)。高德美的全球美學(xué)注射醫(yī)師網(wǎng)絡(luò)（GAIN）今年迎來了其10 周年慶典，作為高德美長期設(shè)立的全球交流平臺，GAIN旨在通過創(chuàng)建一個由臨床經(jīng)驗豐富的美學(xué)從業(yè)者組成的獨特社區(qū)，為其提供交流、啟發(fā)和賦能。

作為這一持續(xù)承諾的一部分，高德美將在大會上舉辦一場題為“GAIN 辯論：塑造我們的美學(xué)人生——聚焦有影響力的治療”的專題研討會，該研討會將于歐洲中部時間 1 月 31 日（星期五）上午 10:30至12:30在 Amphi Bleu 舉行。另一場主題為 “高德美創(chuàng)新：美學(xué)與科學(xué)的交匯” 的醫(yī)學(xué)專題研討會也將于歐洲中部時間 1 月 31 日（星期五）上午 9:00 至10:00在 4 樓 Regency 3 + 4 舉行。

高德美還將舉辦一場關(guān)于注射劑使用的大師班課程，討論如何應(yīng)對藥物引起的體重減輕對美學(xué)的具體需求。該課程將于歐洲中部時間1 月 30 日（星期四）下午 2:00至4:00在 Salon d’honneur舉行。同時，五場“專家見面會”將進(jìn)一步鞏固高德美作為皮膚學(xué)領(lǐng)域領(lǐng)導(dǎo)者的獨特地位。會議將探討包括皮膚質(zhì)量、全程膠原蛋白和彈性蛋白刺激，以及重新定義透明質(zhì)酸（HA） 填充劑以創(chuàng)新自然效果的主題，并深入探討 Alastin®、塑妍萃®和新型液態(tài)A型肉毒毒素等產(chǎn)品。這些活動將在高德美展臺舉行，并將在 @GAINbyGalderma Instagram 賬號上進(jìn)行直播。

說明：瑞藍(lán) SHAYPE、瑞藍(lán)· Refyne?尚未于中國大陸地區(qū)上市

References

參考資料

1.Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at: TOXINS 2021; Jan 16-17, 2021; virtual meeting

2.Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at: TOXINS 2022; July 27-30, 2022; New Orleans, LA

3.Shridharani SM, et al. Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines. ASJ. 2024; sjae131

4.Ablon G, et al. Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study. Dermatol Surg. 2024. doi: 10.1097/DSS.0000000000004470

5.Prather HB, et al. Efficacy and safety of a novel formulation liquid botulinum toxin, RelabotulinumtoxinA, when used for combination treatment of glabellar and lateral canthal lines. E-poster presented at: ASDS 2024; October 17-20, 2024; Orlando, Florida, United States

6.Beer K, et al. READY-4: Long-term safety with repeated injections using RelabotulinumtoxinA, a novel liquid formulation botulinum toxin, in the treatment of glabellar and lateral canthal lines. E-poster presented at: ASDS 2024; October 17-20, 2024; Orlando, Florida, United States

7.Relfydess®. EU Summary of Product Characteristics

8.Sculptra®. EU Instructions for Use. 2021. Available online. Accessed January 2025

9.Widgerow A, et al. A randomized, comparative study describing the gene signatures of Poly-L-Lactic Acid (PLLA-SCA) and Calcium Hydroxylapaptite (CaHA)?in the treatment of nasolabial folds. Poster presented at IMCAS World Congress, February 1-3, 2024, Paris, France

10.Galderma. Data on File (MA-60875)

11.Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042

12.Huth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791

13.Philipp-Dormston, W.G., Wong, C., Schuster, B., Larsson, M.K. and Podda, M., 2018. Evaluating perceived naturalness of facial expression after fillers to the nasolabial folds and lower face with standardized video and photography. Dermatologic Surgery, 44(6), pp.826-832.

14.Bromée T, et al. A new hyaluronic acid injectable, HASHA, sets new G-prime standards. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

15.Moradi A, et al. Aesthetic improvement and subject satisfaction with liquid relabotulinumtoxinA treatment of glabellar lines in a 12-month, randomized, controlled trial. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France

16.Lekholm E, et al. RelabotulinumtoxinA, a ready-to-use formulation neuromodulator manufactured with PEARL? technology to maintain high potency and specific activity. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

17.Nestor M, et al. RelabotulinumtoxinA did not induce the formation of neutralizing antibodies across almost 1700 subjects treated in the Phase III Program. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

18.Bertucci V, et al. Treatment of Glabellar Lines and Lateral Canthal Lines with RelaBoNT-A Across Different Ethnicity and Race: Pooled Data from Three Phase III Studies. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

19.Fabi S, et al. Regenerative aesthetic effects of poly L-lactic acid (Sculptra®) treatment. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

20.Haddad A, et al. Comparing poly L-lactic acid (PLLA-SCA) and calcium hydroxylapatite (CaHA-R) in-vivo. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

21.Avelar L, et al. Comparing two biostimulators on the local tissue response and degradation in-vivo with an indirect comparison to clinical outcomes. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

22.Markowitz O, et al. Evaluation of synergistic effects for midface improvement when pairing Sculptra® (PLLA-SCA) with Alastin skincare®: A comparative study. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

23.Nikolis A, et al. Hyaluronic acid fillers preserve natural movement and dynamic expression: data from three Phase IV clinical trials. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

24.Persson C, et al. Patient and Investigator Treatment Experience with Ready-to-Use AbobotulinumtoxinA Solution Versus Powder BotulinumtoxinA for Treatment of Glabellar Lines. Abstract presented at TOXINS 2024; Jan 17-20, 2024, Berlin

25.U.S. Food and Drug Administration. Sculptra summary of safety and effectiveness data. Available online. Accessed January 2025.

26.Galderma. Data on File (MA-46589)

27.Duracinsky M, et al. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis. 2014;14(474). doi:10.1186/1471233414474

28.Zhang S and Duan E. Fighting against Skin Aging: The Way from Bench to Bedside. Cell Transpl. 2018;27(5):729-738. doi: 10.1177/0963689717725755

29.Asius J, et al. Inventors. US patent US 7,731,758 B2.2010. Available online. Accessed January 2025

30.Morgan P, et al. Product Manufacturing Process for Poly-L-lactic acid (PLLA-SCA). Poster presented at IMCAS World Congress, January 26–28, 2023, Paris, France

31.Galderma. Data on File (MA-53568)

32.Shuster S, et al. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-43. doi: 10.1111/j.1365-2133.1975.tb05113.x

33.Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39:915–22

34.Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48: 101–108. doi: 10.1097/DSS.0000000000003239

35.Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024, October 17-20, 2024, Orlando, Florida, United States

36.Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapetite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting, October 17-20, 2024, Orlando, Florida, United States

37.Haddad S, et al. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022;61:1284–1288. doi: 10.1111/ijd.16229

38.Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51

39.Hexsel D, et al. Introducing the L-Lift-A Novel Approach to Treat Age-Related Facial Skin Ptosis Using A Collagen Stimulator. Dermatol Surg. 2020;46(8):1122–1124. doi:10.1097/DSS.0000000000002015

40.Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC, March 30 - April 1, 2023, Monaco

41.Di Gregorio C. 25+ Years of Experience with the Restylane Portfolio of Injectable Hyaluronic Acid Fillers for Facial Aesthetic Treatment. E-poster presented at AMWC, March 27-29, 2024, Monaco

42.Nikolis A, et al. The Role of Clinical Examination in Midface Volume Correction Using Hyaluronic Acid Fillers: Should Patients Be Stratified by Skin Thickness? Aesthet Surg J Open Forum. 2020; 2(1):1–12.

43.Galderma. Data on file. Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021

44.Restylane U.S. Instructions For Use. Available online. Accessed January 2025.

45.Kablik J, et al. Comparative Physical Properties of Hyaluronic Acid Dermal Fillers: Dermatologic Surgery 35, 302–312 (2009).

46.Narins RS, et al. Persistence of nasolabial fold correction with a hyaluronic acid dermal filler with retreatment: results of an 18-month extension study. Dermatol Surg. 2011;37:644–650

47.Talarico S, et al. High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg. 2015;41:1361–1369

48.Ohrlund A, et al.. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. JDD. 2024; 23(1), pp.1332-1336.

49.Solish N, et al. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-46.

50.Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after hyaluronic acid filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-6.

相關(guān)知識

塑妍萃?Sculptra?在華獲批中面部適應(yīng)癥 高德美有力推進(jìn)注射美學(xué)在華全面布局
潮流文化視角下的美學(xué)機遇和挑戰(zhàn) 高德美發(fā)布《前顏NEXT》全球美學(xué)趨勢報告
為我代「顏」，美出個性 高德美個性美學(xué)整體定治方案HIT?中國發(fā)布
體重管理產(chǎn)業(yè)鏈火力全開，華東醫(yī)藥全面布局減重領(lǐng)域及醫(yī)美領(lǐng)域
自在豐盈，靈動出采 高德美瑞藍(lán)豐采?暨“個性提升之美”面部美學(xué)定治方案 中國上市
16部委聯(lián)合制定“體重管理年”，華東醫(yī)藥前瞻性布局體重管理產(chǎn)業(yè)鏈?導(dǎo)語：$華東醫(yī)藥(SZ000963)$?在減重藥物和醫(yī)美領(lǐng)域積極布局，推出多款減重和塑形產(chǎn)品，成為國內(nèi)首個獲批減肥適應(yīng)癥...
高德美OBT技術(shù)中國首秀瑞藍(lán)·定采?上市，開啟玻尿酸動態(tài)美學(xué)新時代
最新！2023健康產(chǎn)業(yè)品牌榜發(fā)布
高德美推出全球領(lǐng)先“個性化面部美學(xué)診療評估體系A(chǔ)ART”
高德美瑞藍(lán)豐采暨“個性提升之美”面部美學(xué)定治方案在中國上市

網(wǎng)址: IMCAS 2025：高德美發(fā)布塑妍萃? 等美學(xué)產(chǎn)品最新數(shù)據(jù)，再次彰顯行業(yè)領(lǐng)導(dǎo)地位 http://m.u1s5d6.cn/newsview1073275.html